ARCHIVES

Amgen Says ESA Use Dropped By Half In Fourth Quarter.

This article is from The Cancer Letter archive.

Vol. 34 No. 03 | January 25, 2008

Download PDF Visit The Full Archive

Related Articles

RFA Available: Chemoprevention Trials

August 5, 1994

House Subcommittee Recommends $137.7 Million Increase For NCI

June 21, 1996

FDA Approval of Abraxane Sets Stage for Competition Between Taxane Drugs. Abraxane a Nanotechnology Drug? Sponsor Says Yes, FDA Says.

January 14, 2005

UC Davis Coordinates Asian American Network

September 27, 2002

In Brief: House Budget Committee Proposes 5% Cut To NIH In FY96; Steady Reductions Expected

March 24, 1995

FDA Authority To Remove Paclitaxel Patent Questioned.

February 9, 2001